Gozetotide — Drug Intelligence | 20 EU Trials

Filter these 20 trials by condition, phase, country and more.

Open in Search →

20 Registered trials

9 Recruiting

9 Completed trials

11 Sponsors

15 Countries

Phase III

Phase II

Phase III: 8 Phase II: 8 Phase I/II: 1 Phase III/IV: 1 Phase I (Other): 1 Phase I (FiH): 1

Oversight events:

13 unexpected events across 7 trials

View oversight register →

Indications tested

Prostate cancer metastatic 2 Hormone-dependent prostate cancer 1 Prostate cancer recurrent 1 Hormone-refractory prostate cancer 1

Sponsors using this IMP

Novartis Pharma AG 9 Medical University Of Vienna 2 Canisius Wilhelmina Ziekenhuis 1 Centre Hospitalier Regional Et Universitaire De Brest 1 Cliniques Universitaires Saint-Luc 1 Hospices Civils De Lyon 1 Karolinska University Hospital 1 Point Biopharma Inc. 1 Radboud universitair medisch centrum Stichting 1 Unicancer 1 Universitaetsklinikum Essen AöR 1

All trials

20 total

PSMA PET For intermediate- or high-risk prostate cancer prior to RadioTherapY: A prospective interventional randomized clinical trial (P4RTY… Pending

2023-506032-33-00 Phase III 1 country Universitaetsklinikum Essen AöR
Multicentric study evaluating the usefulness of early PSMA PET scan in metastatic renal cancer requiring standard immunotherapy treatment. Pending

2024-517098-26-00 Phase II 1 country Cliniques Universitaires Saint-Luc
A clinical trial to learn about the effects of AMO959 given with AAA617 and an androgen receptor pathway inhibitor (ARPI) in adults with PSM… Recruiting

2025-521859-23-00 Phase I/II 4 countries Novartis Pharma AG
ISEE-RCC study Recruiting

2024-514181-39-00 Phase III 1 country Stichting Radboud universitair medisch centrum
ReaLuP : Study on Re-treatment with Radiopharmaceutical Drug [177Lu]Lu-PSMA in Patients With Metastatic Castration-Resistant Prostate Cancer Recruiting

2024-512043-22-00 Phase II 1 country Hospices Civils De Lyon
Neoadjuvant [177Lu]Lu-PSMAI&T radioligand therapy (PSMA-RLT) for patients with oligometastatic prostate cancer diagnosed using [68Ga]Ga-PSMA… Recruiting

2024-519377-18-00 Phase II 1 country Medical University Of Vienna
[177Lu]Lu-PSMAI&T radioligand therapy (PSMA-RLT) for patients with prostate cancer and biochemical but not radio-morphological local recurre… Recruiting

2024-519348-34-00 Phase II 1 country Medical University Of Vienna
A Phase I, open-label, multi-center study of radiation dosimetry, safety, and tolerability of extended lutetium (177Lu) vipivotide tetraxeta… Recruiting

2024-512338-13-00 Phase I (Other) 3 countries Novartis Pharma AG
Study evaluating whether giving 177Lu-PSMA-617 to men having a spreading prostate cancer which does not respond well to the current standard… Recruiting

2022-502408-57-00 Phase III 6 countries Unicancer
An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617… Recruiting

2022-502956-29-00 Phase III 11 countries Novartis Pharma AG
A study to compare conventional "salvage" radiotherapy and individualized treatment based on results from PSMA PET/CT assessments in patient… Recruiting

2023-504917-54-00 Phase III 1 country Karolinska University Hospital
A Phase II, randomized, open-label, multi-center study of JSB462 (luxdegalutamide) in combination with lutetium (177Lu) vipivotide tetraxeta… Ended

2024-520155-24-00 Phase II 7 countries Novartis Pharma AG
Multi-institutional Evaluation of the Cost-effectiveness of PSMA-PET/CT for the Detection of Pelvic Lymph Node Invasion in Newly Diagnosed P… Ended

2024-518171-59-00 Phase III/IV 1 country Canisius Wilhelmina Ziekenhuis
An Open-label Dosimetry, Tolerability and Safety Study of lutetium (177Lu) vipivotide tetraxetan in Patients with Progressive PSMA-Positive … Ended

2023-503925-20-00 Phase II 4 countries Novartis Pharma AG
An international prospective open-label, multi-center, randomized, non-comparative phase II study of lutetium [177Lu] vipivotide tetraxetan … Ended

2022-503040-41-00 Phase II 7 countries Novartis Pharma AG
SatisfACtion: A Phase I/II, open-label, multi-center study of [225Ac]Ac-PSMA-R2 in men with metastatic hormone sensitive prostate cancer (mH… Ended

2023-507672-52-00 Phase I (FiH) 1 country Novartis Pharma AG
Lutetium after second-line hormonal treatment [PBP-301] [SPLASH] Ended

2024-515604-39-00 Phase III 3 countries Point Biopharma Inc.
PSMAfore: A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therap… Ended

2023-507772-50-00 Phase III 9 countries Novartis Pharma AG
An Open-label study comparing 177Lu-PSMA-617 plus Standard of Care vs. Standard of Care in the Treatment of mHSPC Ended

2023-507970-42-00 Phase III 10 countries Novartis Pharma AG
Diagnostic Performance of Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) Imaging for Pr… Ended

2024-516319-25-00 Phase II 1 country Centre Hospitalier Regional Et Universitaire De Brest

Showing 1–20 of 20 trials

← All drugs A–Z